ICON Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution


Founding member of Align Clinical CRO to help create open technology standards that make it easier for CROs and sponsors to work together during trials

Dublin, 29 March 2018 – ICON plc, (NASDAQ: ICLR) today announced it is a founding member of Align Clinical CRO, a new industry technology standards group dedicated to making it easier for life sciences companies and contract research organizations (CROs) to collaborate during clinical trials. ICON is joining six leading CROs to create open technology standards intended to simplify trial execution and improve the productivity and efficiency of clinical trials.

Align Clinical CRO represents the first time global CROs are coming together to develop open technology standards to transform clinical trial operations across the life sciences industry. As part of Align Clinical CRO, ICON is committed to developing standards that drive greater consistency in study execution and accelerate product development in life sciences.

“The volume and type of data being generated per patient visit in clinical trials continues to grow exponentially, so technology standards to gather, manage and exchange this data is critical. Align Clinical CRO provides a unique opportunity to define these technology standards and better enable the life sciences industry to bring new drugs and devices to market faster,” commented Tom O’Leary, CIO at ICON.

ICON will work alongside members, with input from across the industry, to create standards intended to help increase sponsor and CRO productivity, reduce operational costs, and run faster trials. The group’s first standard is anticipated to be an Operational Data Exchange to facilitate seamless information sharing and make it easier for sponsors and CROs to work together during clinical trials.

“There is tremendous potential to enhance clinical trial execution with common technology standards that benefit the entire industry,” said Henry Levy, president of Align Clinical CRO. “The assembly of Align Clinical CRO represents an important industry collaboration to improve the trial process and how the industry works together to accelerate drug development.”

Visit AlignClinicalCRO.org to learn about the group’s mission and stay up-to-date on the standards in development.

About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 38 countries and has approximately 13,250 employees.

About Align Clinical CRO
Align Clinical CRO is an industry standards group founded by Veeva Systems and the world’s largest CROs, including ICON plc, Medpace, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Syneos Health, and UBC. The group is dedicated to creating open technology standards that improve trial execution and collaboration with life sciences companies, making it easier for sponsors and CROs to work together during clinical trials. For more information, visit www.alignclinicalcro.org.
 

ICON Media Contact
Olivia Pimenta
Weber Shandwick
+44 (0)207 067 0557
OPimenta@webershandwick.com

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.